



Review

Neurophysiology of synaptic functioning in multiple sclerosis



Mario Stampanoni Bassi^a, Francesco Mori^{a,b}, Fabio Buttari^{a,b}, Girolama A. Marfia^{a,b}, Andrea Sancesario^a, Diego Centonze^{a,b,*}, Ennio Iezzi^a

^aNeurology and Neurorehabilitation Units, IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Via Atinense 18, 86077 Pozzilli (IS), Italy

^bMultiple Sclerosis Research Unit, Department of Systems Medicine, Tor Vergata University, Via Montpellier 1, 00133 Rome, Italy

ARTICLE INFO

Article history:

Accepted 8 April 2017

Available online 24 April 2017

Keywords:

Multiple sclerosis

Experimental autoimmune

encephalomyelitis

Inflammatory cytokines

Synaptic plasticity

Transcranial magnetic stimulation

Neurodegeneration

HIGHLIGHTS

- Excitotoxicity is emerging as a crucial determinant of early neurodegeneration in MS.
- Specific inflammatory cytokines alter glutamatergic and GABAergic transmission.
- Compensatory plasticity can influence both clinical recovery and disease progression.

ABSTRACT

Multiple sclerosis (MS) is an inflammatory immune-mediated disorder of the central nervous system (CNS), primarily affecting the myelin sheath and followed by neurodegeneration. Synaptic alterations are emerging as critical determinants of early neurodegeneration in MS.

Inflammation-induced alterations of synaptic transmission and plasticity have been investigated in vitro and also in human MS using transcranial magnetic stimulation (TMS) techniques. Specific inflammatory cytokines alter glutamatergic and GABAergic transmission, resulting in synaptic hyperexcitability. In both experimental autoimmune encephalomyelitis (EAE) and MS, excitotoxic damage and neurodegeneration are found even in the early phases of disease, conversely inflammation persists in the progressive phases.

Inflammatory cytokines also affect synaptic plasticity, as both long-term potentiation (LTP) and long-term depression (LTD) are altered in EAE and in MS patients. In particular, inflammation profoundly subverts plasticity and influence both clinical recovery after a relapse and disease course. Regulation of neuronal activity by cytokines plays important roles in the neuro-immune crosstalk involved in inflammation-associated excitotoxic neuronal damage, and in the chance of developing compensatory plasticity.

Innate and adaptive immunity interact with the CNS in MS, in line with the concept that cytokines and chemokines, in concert with neurotransmitters and neuropeptides, represent a major communication system in the CNS.

© 2017 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Contents

1. Introduction	1149
2. Inflammation and synaptic transmission in EAE	1149
2.1. Glutamatergic transmission	1149
2.2. GABAergic transmission	1150
3. Inflammation and synaptic transmission in MS	1151

* Corresponding author at: Multiple Sclerosis Research Unit, Department of Systems Medicine, Tor Vergata University, Via Montpellier 1, 00133 Rome, Italy. Fax: +39 06 7259 6006.

E-mail addresses: mario_sb@hotmail.it (M. Stampanoni Bassi), mrofn01@uniroma2.it (F. Mori), fabio.buttari@ptvonline.it (F. Buttari), marfia@uniroma2.it (G.A. Marfia), andrea.sancesario@hotmail.it (A. Sancesario), centonze@uniroma2.it (D. Centonze), ennio.iezzi@neuromed.it (E. Iezzi).

<http://dx.doi.org/10.1016/j.clinph.2017.04.006>

1388-2457/© 2017 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

3.1.	TMS protocols	1151
3.1.1.	Resting motor threshold and stimulus/response curves	1151
3.1.2.	Central motor conduction time	1151
3.1.3.	Silent period	1151
3.1.4.	Intracortical inhibition and facilitation	1151
3.2.	TMS studies of synaptic functioning in MS patients	1151
4.	Inflammation and plasticity in EAE and MS	1152
4.1.	Synaptic plasticity	1152
4.2.	Synaptic scaling and activity-dependent plasticity in EAE	1153
4.3.	TMS-induced plasticity in MS patients	1153
4.4.	LTP reserve in MS	1154
5.	Cytokines, chemokines, and neuro-immune crosstalk	1154
6.	Conclusion	1155
7.	Conflicts of interest	1155
	Acknowledgements	1155
	References	1155

1. Introduction

Multiple sclerosis (MS) is an inflammatory, immune-mediated disorder of the central nervous system (CNS) which is classically considered a pathology of the myelin sheath followed by late brain and spinal atrophy. Independently of white matter pathology, synaptic alterations and in particular excitotoxic damage are emerging as critical determinants of early neurodegeneration in MS. In line with the excitotoxic hypothesis, in animal models of MS (experimental autoimmune encephalomyelitis, EAE), both enhanced glutamatergic signaling and reduced GABAergic transmission have been described (Castegna et al., 2011; Clements et al., 2008; Centonze et al., 2009; Gottesfeld et al., 1976; Kan et al., 2014; Pitt et al., 2000; Sarchielli et al., 2003; Rossi et al., 2011b; Werner et al., 2001). In addition, altered levels of both glutamate and GABA have been reported in the cerebro-spinal fluid (CSF) (Sarchielli et al., 2003; Stover et al., 1997) and in the brain of MS patients (Cawley et al., 2015; Srinivasan et al., 2005). Furthermore, both in EAE and MS altered glutamate clearance and receptor expression have been found (Hardin-Pouzet et al., 1997; Pitt et al., 2000; Smith et al., 2000; Ohgoh et al., 2002; Geurts et al., 2003, 2005; Vallejo-Illarramendi et al., 2006). Accordingly, oligodendrocyte and neuronal damage is partly prevented by the administration of glutamate receptor antagonists (Bolton and Paul, 1997; Centonze et al., 2009; Pitt et al., 2000; Smith et al., 2000; Wallström et al., 1996; Plaut, 1987). Overall, the excitotoxic hypotheses contribute to add novelty on both the pathogenesis and prognosis of MS.

In the first and in the second part of this review article, we will summarize the experimental studies showing that in EAE and MS specific proinflammatory cytokines induce alterations of both glutamatergic and GABAergic transmission, resulting in synaptic hyperexcitability. Proinflammatory cytokines, such as interleukin-1 β (IL-1 β) and tumor necrosis factor α (TNF α), are soluble mediators released by immune cells, able to activate inflammatory response. We will also overview the clinical studies in MS patients using transcranial magnetic stimulation (TMS), showing alterations of both excitatory and inhibitory intracortical circuits in relation to different phenotypes and disease phases.

In the third part, we will discuss studies exploring neural plasticity either in vitro or in MS patients, using TMS. Brain plasticity and its influence on clinical expression have been explored in experimental models of MS. In EAE mice, inflammatory lesions of the corticospinal tract (CST) induce anatomical changes in the connections of the spared neighboring interneurons and in the projections of unlesioned CST fibers, leading to a functional remodeling of motor cortex which is important for clinical recovery (Kerschensteiner et al., 2004). Morphological changes of spinal

motoneuron synapses have also been investigated in EAE during exacerbation and after remission. In particular, both synaptic retraction during disease exacerbation and recovery of presynaptic contacts during remission phase have been reported (Marques et al., 2006). Also in MS patients, both cortical synaptic loss and increased synaptogenesis compared to controls have been described (Wegner et al., 2006; Schirmer et al., 2013). In this part, we will focus on TMS studies performed in MS patients, which highlighted that specific plasticity alterations are associated with different disease phenotypes (relapsing-remitting, RR-MS; primary progressive, PP-MS), or phase (remitting, relapsing), and that a specific subset of inflammatory cytokines is responsible for these alterations. In this scenario, long-term potentiation (LTP) seems to be able to minimize neuronal damage, bringing back the excitability of those neurons which have partly lost synaptic inputs. These phenomena seem to modulate the clinical expression of disease and disability progression. Moreover, the concept of plasticity reserve is emerging as a new marker to predict clinical recovery.

In the last part, we will examine the role of different proinflammatory and anti-inflammatory cytokines, together with neurotrophic factors, on synaptic function and disease manifestations. It has been demonstrated that cytokines can influence both neuronal survival and clinical manifestation by modulating synaptic transmission (Centonze et al., 2009; Rossi et al., 2011a). Overall, these data are in line with the hypothesis that cytokines and chemokines, together with neurotransmitters and neuropeptides, represent a major communication system in the CNS.

2. Inflammation and synaptic transmission in EAE

2.1. Glutamatergic transmission

In a previous study (Centonze et al., 2009), we have first investigated the effects of inflammation on synaptic transmission in the striatum of EAE mice. We found that aberrant excitatory transmission was associated with altered function of the main ionotropic glutamate receptor, termed α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor channel complex (Fig. 1). These alterations occurred even before the clinical manifestations and were associated to neurodegeneration, supporting the notion that in MS the neuronal compartment and the white matter are involved together, although independently (Centonze et al., 2009). It has been previously suggested that AMPA receptors are involved in the neurodegeneration of EAE (Kanwar et al., 2004), this was further confirmed by the evidence that administration of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzoquinoline-2,3-dione

Download English Version:

<https://daneshyari.com/en/article/5627819>

Download Persian Version:

<https://daneshyari.com/article/5627819>

[Daneshyari.com](https://daneshyari.com)